S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

PhaseBio Pharmaceuticals Stock Forecast, Price & News

+0.01 (+0.45%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
263,185 shs
Average Volume
269,200 shs
Market Capitalization
$107.72 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Malvern, PA.


PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
December 21, 2021 |  finance.yahoo.com
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
November 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$320 thousand
Book Value
($0.86) per share


Net Income
$-98.57 million
Pretax Margin




Free Float
Market Cap
$107.72 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.98 out of 5 stars

Medical Sector

638th out of 1,405 stocks

Pharmaceutical Preparations Industry

307th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

Is PhaseBio Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals
or view top-rated stocks.

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHAS shares have decreased by 28.4% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for PhaseBio Pharmaceuticals

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analysts' expectations of $2.67 million.
View PhaseBio Pharmaceuticals' earnings history

What price target have analysts set for PHAS?

3 brokerages have issued 1-year price objectives for PhaseBio Pharmaceuticals' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 569.6% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Jonathan P. Mow, Chief Executive Officer & Director
  • John P. Sharp, Chief Financial Officer
  • John S. Lee, Chief Medical Officer
  • Kristopher L. Hanson, Secretary, Vice President & Head-Legal
  • Susan E. Arnold, Vice President-Preclinical & CMC

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Spire Wealth Management (0.53%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, Edmund Harrigan and Glen Burkhardt.
View institutional ownership trends for PhaseBio Pharmaceuticals

Which major investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was acquired by a variety of institutional investors in the last quarter, including Spire Wealth Management. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, and Edmund Harrigan.
View insider buying and selling activity for PhaseBio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $2.24.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals has a market capitalization of $107.72 million and generates $320 thousand in revenue each year. The company earns $-98.57 million in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does PhaseBio Pharmaceuticals have?

PhaseBio Pharmaceuticals employs 50 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

Where are PhaseBio Pharmaceuticals' headquarters?

PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Parkway Suite 30, Malvern PA, 19355.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at (610) 981-6500 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.